iGlarLixi CGM Study in Chinese T2D Individuals After OADs

Exclusion Criteria

• •Participants with severe renal dysfunction
• •Participants with short life expectancy
• •Participants with conditions/concomitant diseases making them non evaluable for the efficacy endpoints
• •Participants with conditions/concomitant diseases precluding their safe participation in this study
• •An episode of severe hypoglycemia requiring the assistance of a third party within 3 months before screening visit
• •History of clinically significant pancreatitis or severe gastrointestinal disorders
• •Participants who have any history of severe multiple allergies or an allergy resulting in anaphylaxis, or contraindication/hypersensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
• •Previous treatment with insulin
• •Use of any glucose-lowering agents other than metformin alone or in combination with a second OAD (can be a SU, a glinide, an alpha-GI, a DPP-4i, or a SGLT-2i)
• •Use of systemic glucocorticoids
• •Use of weight loss drugs
• •History of discontinuation of a previous treatment with GLP-1 RA for safety/tolerability reasons or lack of efficacy
• •Laboratory findings at the screening visit
• •Participants have any current or previous skin conditions
• •Participants unwilling or unable to do blood glucose monitoring using the Sponsor-provided blood glucometer at home
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.